Today's noteworthy upgrades include: Abiomed (ABMD) upgraded to Outperform from Market Perform at Raymond James... AcelRx (ACRX) assumed with a Buy from Hold at Jefferies... BE Aerospace (BEAV) upgraded to Buy from Hold at Canaccord... CONE Midstream (CNNX) upgraded to Outperform from Neutral at Baird... Centamin (CELTF) upgraded to Neutral from Reduce at Nomura... Chemtura (CHMT) upgraded to Buy from Accumulate at Seaport Global... Fluidigm (FLDM) upgraded to Buy from Hold at Cantor... GNC Holdings (GNC) upgraded to Overweight from Equal Weight at Stephens... Guidewire (GWRE) upgraded to Buy from Neutral at Citi... Imperva (IMPV) upgraded to Buy from Hold at Topeka... Interface (TILE) upgraded on valuation at Stifel... LinkedIn (LNKD) upgraded to Buy from Neutral at Sterne Agee CRT... Live Nation (LYV) upgraded to Overweight from Market Perform at Albert Fried... Marathon Oil (MRO) upgraded to Overweight from Neutral at Atlantic Equities... MiMedx (MDXG) upgraded to Outperform from Market Perform at Northland... NVIDIA (NVDA) upgraded to Equal Weight from Underweight at Morgan Stanley... New Oriental Education (EDU) upgraded to Outperform from Neutral at Macquarie... New York Community Bancorp (NYCB) upgraded to Market Perform at Keefe Bruyette... ON Semiconductor (ON) upgraded to Outperform from Neutral at Wedbush... Olin Corp. (OLN) upgraded on positive catalysts at RBC Capital... PPL Corp. (PPL) upgraded to Buy from Hold at Deutsche Bank... Pilgrim's Pride (PPC) upgraded to Outperform from Market Perform at BMO Capital... Piper Jaffray (PJC) upgraded to Outperform from Market Perform at Keefe Bruyette... Regis (RGS) upgraded to Neutral from Sell at Northcoast... Santander Mexico (BSMX) upgraded to Overweight from Neutral at JPMorgan... Seattle Genetics (SGEN) upgraded to Neutral from Underweight at Piper Jaffray... Trimble (TRMB) upgraded to Outperform from Neutral at Baird... Vertex (VRTX) upgraded to Buy from Neutral at H.C. Wainwright... YRC Worldwide (YRCW) upgraded on results at Stifel.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Microsoft (MSFT) is scheduled to report results of the third quarter of its fiscal year 2024 after the market close on Thursday, April 25, with a conference call scheduled for 5:30 pm ET. What to watch... To see the rest of the story go to thefly.com. See Story Here

BofA raised the firm's price target on Texas Instruments (TXN) to $190 from $175 and keeps a Neutral rating on the shares. TI's small Q1 beat and inline but sequentially rising Q2 sales guidance, "while modest, potentially marks a recovery inflection in industrial chip demand," with positive read-across for U.S. peers such as Analog Devices (ADI), Microchip (MCHP), NXP Semiconductors (NXPI) and On Semiconductor (ON), the analyst tells investors. However, despite an expected recovery, TI's sustained high capex intensity could keep reported calendar year 2024-26 pro-forma EPS below $6 per share, the analyst added.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSAudioEye (AEYE) up... To see the rest of the story go to thefly.com. See Story Here

Wells Fargo lowered the firm's price target on On Semiconductor (ON) to $95 from $110 and keeps an Overweight rating on the shares ahead of quarterly results. The firm anticipates On to deliver a Q2 guide slightly below expectations as it adjusts to Tesla-specific (TSLA) production softness specific to image sensor and SiC sales.

Vertex Pharmaceuticals and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex's cell therapies for type 1 diabetes, or T1D. TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies. TreeFrog's proprietary technology platform, C-Stem, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.